pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,109 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1871Endpoints1449Fierce Biotech767BioSpace758BioPharma Dive548raps249onclive165fda recalls120
therapy area
allOncology12936Rare Disease3340Immunology3024Cardiology2859Hematology2298Pulmonology2255Vaccines
  • FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drug
    The U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
    STAT · 23h agoCRLNegative↗ source
  • FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefit
    The U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
    BioPharma Dive · 23h agoRegulatoryNegative↗ source
← prev
page 2 of 165
next →
fda medwatch115
globenewswire health73
fda press62
1854
Psychiatry & CNS1232
Ophthalmology1135
Endocrinology & Metabolism807
Pain791
Nephrology786
  • Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cuts
    At the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
    BioSpace · 1d agoNeutral↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 1d agoDealNeutral↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 1d agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 1d agoDealNeutral↗ source
  • Epic Systems pledges broader AI access to its EHR data and defends its competitive practices at HLTH conference
    Epic Systems executives used a panel at the HLTH conference to respond to a STAT investigation that accused the company of limiting data access for rival developers. The company said it will make…
    STAT · 14h agoRegulatoryNeutral↗ source
  • Experts warn of safety risks as FDA targets compounded GLP-1 weight-loss drugs sold by telehealth firms
    At the HLTH conference, experts highlighted growing concerns about telehealth companies that sell compounded GLP-1 weight-loss medications. These firms create custom formulations and ship them dir…
    BioPharma Dive · 19h agoRegulatoryNegative↗ source
  • Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concerns
    The Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…
    STAT · 23h agoRegulatoryNeutral↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 1d agoNegative↗ source
  • Loss of Senate Appropriations Chair Susan Collins could weaken scientists’ fight against new research oversight rule
    Senator Susan Collins, the Republican chair of the Senate Appropriations Committee, was defeated in her re‑election, ending her role as the most prominent GOP ally for science advocates. Scientist…
    STAT · 1d agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton's nomination to lead the FDA amid Senate Republican concerns
    The White House announced it is withdrawing its nominee, Heidi Overton, for FDA commissioner. Overton, a preventive care physician who previously served in the Trump administration, faced resistan…
    STAT · 1d agoRegulatoryNegative↗ source
  • STAT+: Influential preventive services panel to meet for first time in more than a year
    A task force, meeting after a long delay, will discuss coverage of treatments for cervical cancer, perinatal depression, and alcohol use.
    STAT · 16h agoRegulatoryNeutral↗ source
  • AI scribe market sees early winners and losers as HLTH conference highlights industry shifts
    The latest AI Prognosis newsletter from STAT examines how the artificial-intelligence scribe sector is beginning to separate into clear frontrunners and laggards. At the HLTH conference, a Startup…
    STAT · 18h agoNeutral↗ source
  • 8 companies hiring in North Carolina now
    Looking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.
    BioSpace · 23h agoRegulatoryNeutral↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 1d agoNeutral↗ source
  • Senate health panel blocks Trump pick for NSF over science integrity concerns
    The Senate health committee rejected the nomination of Jim O’Neill to lead the National Science Foundation after Chair Bill Cassidy voiced doubts about his commitment to scientific integrity. Cass…
    STAT · 22h agoRegulatoryNegative↗ source
  • Quanterix CEO Everett Cunningham resigns after ten months, interim leader appointed
    Quanterix announced that Everett Cunningham will leave his role as president and chief executive officer after serving less than a year. The company said he will step down to pursue another opportu…
    Fierce Biotech · 1d agoNeutral↗ source
  • NIH to relocate its final research chimpanzees to sanctuary in Texas next year
    The National Institutes of Health announced that the last group of government‑owned chimpanzees still housed in a laboratory will be moved to a sanctuary early next year. The animals, about three d…
    STAT · 17h agoPositive↗ source
  • Opinion calls for impeachment of Health Secretary Robert F. Kennedy Jr. over anti‑vaccine stance
    Professor Paul Knoepfler, a cell‑biology faculty member at UC Davis, argues that the post‑midterm political climate creates a window to remove Health and Human Services Secretary Robert F. Kennedy…
    STAT · 1d agoNegative↗ source
  • Opinion argues that traditional four-year medical schools may be outdated for pre-clerkship training
    Alex Serafini, a fourth‑year medical student at Icahn School of Medicine, contributes to a new First Opinion series that questions the structure of modern medical education. He notes that over the…
    STAT · 1d agoNeutral↗ source
  • Why comparing every new employer to your last one can hurt your influence
    Executive coach Angela Justice advises professionals not to treat their former workplace as the standard for every new job. She says the habit can cloud judgment and reduce a person's influence. W…
    BioSpace · 1d agoNeutral↗ source